[
    {
        "headline": "What Makes Bio-Techne Corporation (TECH) a Compelling Addition?",
        "text": "Polen Capital, an investment management company, released its “Polen U.S. Small Company Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q1 2025, optimism fueled by the Trump election shifted to fear and uncertainty due to apprehension about cost-cutting measures and emerging trade policies. In the first quarter, […]"
    },
    {
        "headline": "ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)",
        "text": "ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA). The funding totaling $1,025,000 will support the translation of various cell and gene therapy initiatives into the clinic."
    },
    {
        "headline": "Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know",
        "text": "A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains."
    },
    {
        "headline": "Biotech Alert: Searches spiking for these stocks today",
        "text": "These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in"
    },
    {
        "headline": "Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing",
        "text": "Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools today announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular"
    },
    {
        "headline": "Bio-Techne to Present at the BofA Securities 2025 Health Care Conference",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar."
    },
    {
        "headline": "Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ...",
        "text": "Bio-Techne Corp (TECH) reports a 6% organic revenue increase and robust performance in protein sciences, despite facing macroeconomic uncertainties and tariff impacts."
    },
    {
        "headline": "Q3 2025 Bio-Techne Corp Earnings Call",
        "text": "Q3 2025 Bio-Techne Corp Earnings Call"
    },
    {
        "headline": "Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket",
        "text": "TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025."
    },
    {
        "headline": "Bio Techne (TECH) Fell on Negative Funding Environment",
        "text": "Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a fall in equities, while fixed income benefited from perceived safety. The […]"
    },
    {
        "headline": "Is the Options Market Predicting a Spike in BioTechne Stock?",
        "text": "Investors need to pay close attention to TECH stock based on the movements in the options market lately."
    },
    {
        "headline": "Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars",
        "text": "Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was 10.4% above analysts’ consensus estimates."
    },
    {
        "headline": "BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis."
    },
    {
        "headline": "BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025."
    },
    {
        "headline": "ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.",
        "text": "ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. (\"A2\") has been awarded a $300,000 G-Rex® Grant. A2's G-Rex® Grant will enable expeditious process development and qualification of a G-Rex-based production system and will enable A2 to evaluate G-Rex for manufacturing cell therapies."
    },
    {
        "headline": "Earnings To Watch: Bio-Techne (TECH) Reports Q1 Results Tomorrow",
        "text": "Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results tomorrow before market hours. Here’s what you need to know."
    },
    {
        "headline": "Should You Hold Bio-Techne Corp. (TECH) For the Long Term?",
        "text": "Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical […]"
    },
    {
        "headline": "TECH Gears Up to Report Q3 Earnings: Here's What to Expect",
        "text": "Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter."
    },
    {
        "headline": "ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy",
        "text": "ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awarded a $200,000 G-Rex® Grant. March Biosciences' G-Rex® Grant will be used to advance the manufacturing of their lead asset, MB-105, a novel investigational autologous CAR-T cell therapy targeting CD5 for patients with T-cell lymphomas."
    },
    {
        "headline": "Bio-Techne Corporation (TECH) Slid Due to NIH’s Funding Concerns",
        "text": "Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market experienced a modest decline in Q1 2025, with the S&P 500 Index falling 4.27%, while bonds showed stability with the Bloomberg U.S. Aggregate Bond Index […]"
    },
    {
        "headline": "What Makes Bio-Techne Corporation (TECH) a Compelling Addition?",
        "text": "Polen Capital, an investment management company, released its “Polen U.S. Small Company Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q1 2025, optimism fueled by the Trump election shifted to fear and uncertainty due to apprehension about cost-cutting measures and emerging trade policies. In the first quarter, […]"
    },
    {
        "headline": "ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)",
        "text": "ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA). The funding totaling $1,025,000 will support the translation of various cell and gene therapy initiatives into the clinic."
    },
    {
        "headline": "Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know",
        "text": "A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains."
    },
    {
        "headline": "Biotech Alert: Searches spiking for these stocks today",
        "text": "These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in"
    },
    {
        "headline": "Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing",
        "text": "Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools today announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular"
    },
    {
        "headline": "Bio-Techne to Present at the BofA Securities 2025 Health Care Conference",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar."
    },
    {
        "headline": "Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ...",
        "text": "Bio-Techne Corp (TECH) reports a 6% organic revenue increase and robust performance in protein sciences, despite facing macroeconomic uncertainties and tariff impacts."
    },
    {
        "headline": "Q3 2025 Bio-Techne Corp Earnings Call",
        "text": "Q3 2025 Bio-Techne Corp Earnings Call"
    },
    {
        "headline": "Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket",
        "text": "TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025."
    },
    {
        "headline": "Bio Techne (TECH) Fell on Negative Funding Environment",
        "text": "Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a fall in equities, while fixed income benefited from perceived safety. The […]"
    },
    {
        "headline": "Is the Options Market Predicting a Spike in BioTechne Stock?",
        "text": "Investors need to pay close attention to TECH stock based on the movements in the options market lately."
    },
    {
        "headline": "Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars",
        "text": "Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was 10.4% above analysts’ consensus estimates."
    },
    {
        "headline": "BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis."
    },
    {
        "headline": "BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025."
    },
    {
        "headline": "ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.",
        "text": "ScaleReady, in collaboration with Wilson Wolf, Bio-Techne Corporation and CellReady, today announced that A2 Biotherapeutics, Inc. (\"A2\") has been awarded a $300,000 G-Rex® Grant. A2's G-Rex® Grant will enable expeditious process development and qualification of a G-Rex-based production system and will enable A2 to evaluate G-Rex for manufacturing cell therapies."
    },
    {
        "headline": "Earnings To Watch: Bio-Techne (TECH) Reports Q1 Results Tomorrow",
        "text": "Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results tomorrow before market hours. Here’s what you need to know."
    },
    {
        "headline": "Should You Hold Bio-Techne Corp. (TECH) For the Long Term?",
        "text": "Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical […]"
    },
    {
        "headline": "TECH Gears Up to Report Q3 Earnings: Here's What to Expect",
        "text": "Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter."
    },
    {
        "headline": "ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy",
        "text": "ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March Biosciences has been awarded a $200,000 G-Rex® Grant. March Biosciences' G-Rex® Grant will be used to advance the manufacturing of their lead asset, MB-105, a novel investigational autologous CAR-T cell therapy targeting CD5 for patients with T-cell lymphomas."
    },
    {
        "headline": "Bio-Techne Corporation (TECH) Slid Due to NIH’s Funding Concerns",
        "text": "Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market experienced a modest decline in Q1 2025, with the S&P 500 Index falling 4.27%, while bonds showed stability with the Bloomberg U.S. Aggregate Bond Index […]"
    },
    {
        "headline": "3 Healthcare Stocks Facing Headwinds",
        "text": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.7%. This drop was worse than the S&P 500’s 7.5% loss."
    },
    {
        "headline": "Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection",
        "text": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope™ technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease pro"
    },
    {
        "headline": "Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning early discovery, translational research, and cell and gene therapy development."
    },
    {
        "headline": "Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks",
        "text": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4."
    },
    {
        "headline": "Reflecting On Research Tools & Consumables Stocks’ Q4 Earnings: Agilent (NYSE:A)",
        "text": "Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (NYSE:A) and its peers."
    },
    {
        "headline": "Bio-Techne to Host Conference Call on May 7, 2025, to Announce Third Quarter Fiscal 2025 Financial Results",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 7, 2025, at 8:00 a.m. CDT to review its third quarter fiscal 2025 financial results."
    },
    {
        "headline": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
        "text": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit"
    },
    {
        "headline": "Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?",
        "text": "Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term."
    },
    {
        "headline": "Q4 Rundown: Avantor (NYSE:AVTR) Vs Other Research Tools & Consumables Stocks",
        "text": "Let’s dig into the relative performance of Avantor (NYSE:AVTR) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season."
    },
    {
        "headline": "Apple, Starbucks upgraded: Wall Street's top analyst calls",
        "text": "Apple, Starbucks upgraded: Wall Street's top analyst calls"
    },
    {
        "headline": "Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks",
        "text": "As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers."
    },
    {
        "headline": "A Look Back at Research Tools & Consumables Stocks’ Q4 Earnings: Mettler-Toledo (NYSE:MTD) Vs The Rest Of The Pack",
        "text": "Let’s dig into the relative performance of Mettler-Toledo (NYSE:MTD) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season."
    },
    {
        "headline": "3 Small-Cap Stocks with Mounting Challenges",
        "text": "Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors."
    },
    {
        "headline": "Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument",
        "text": "Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spatial biology research."
    },
    {
        "headline": "Bio-Techne Opens New Customer Experience Centre in Germany",
        "text": "TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany."
    }
]